MET and medulloblastoma: However, clinical response and outcome to targeted therapy in this patient population have not been described.<h4>Methods</h4>We report on two patients with a history of childhood medulloblastoma who developed RIGs harboring MET fusions treated with the selective MET inhibitor capmatinib.